全国服务咨询热线:

18438616290

Products产品中心
首页 > 产品中心 > 生化试剂 > 小分子化合物 > abs47027853Empagliflozin 864070-44-0

Empagliflozin 864070-44-0

简要描述:Empagliflozin 864070-44-0
Empagliflozin (BI-10773) is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6.

  • 产品型号:abs47027853
  • 厂商性质:生产厂家
  • 更新时间:2026-01-04
  • 访  问  量:600

详细介绍

品牌absinCAS864070-44-0
分子式C23H27ClO7纯度99%
分子量450.91货号abs47027853
规格50mg供货周期现货
主要用途is a potent应用领域化工,生物产业,农林牧渔,制药/生物制药,综合

Empagliflozin 864070-44-0

产品描述
描述

Empagliflozin (BI-10773) is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6.

纯度
99%
储存/保存方法
Store at -20℃ for three years(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
基本信息
别名
依帕列净;恩ge列净;BI-10773;BI 10773;BI10773
外观
White to off white solid
可溶性/溶解性
DMSO : 83 mg/mL (184.1 mM)
生物活性
靶点
SGLT2
In vitro(体外研究)
Empagliflozin shows >2500-fold selectivity for hSGLT-2 over hSGLT-1 (IC50 8300 nM) and >3500-fold selectivity over hSGLT-4, it exhibits >350-fold selectivity over hSGLT-5 (IC50=1100 nM) and >600-fold selectivity over hSGLT-6. No relevant inhibition of GLUT1 is observed up to 10 μM Empagliflozin. In a kinetic binding experiments, -empagliflozin displays a high affinity for SGLT-2 with a mean Kd of 57 nM in the absence of glucose, and shows a half-life of -empagliflozin-binding to SGLT-2 of 59 min in the absence of glucose.Its binding to SGLT-2 is competitive with glucose.
In vivo(体内研究)
High exposure of empagliflozin is achieved in dogs, with plasma concentrations >100-fold above IC50 measured 24 h after administration of 5 mg/kg empagliflozin. The total plasma clearance of empagliflozin in ZDF rat is 43 mL/min/kg, while in dogs is lower at 1.8 mL/min/kg. Cmax of empagliflozin in ZDF rat and dogs is 167 nM and 17254 nM, respectively. Terminal elimination half-life in ZDF rat and dogs is 1.5 h and 6.3 h, respectively. Bioavailability of empagliflozin in ZDF rat is 33.2%, while in dogs is higher at 89.0%. Long-term treatment with empagliflozin, improves glycaemic controland features of metabolic syndrome in diabetic rats.
研究领域
研究领域
Signal TransductionMetabolismPlasma MembraneChannels
Drug DiscoverySmall Molecule DrugLead Compound Discovery
Empagliflozin 864070-44-0温馨提示:本产品仅作科研实验使用,不支持临床等研究

产品咨询

留言框

  • 产品:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 省份:

  • 详细地址:

  • 补充说明:

  • 验证码:

    请输入计算结果(填写阿拉伯数字),如:三加四=7
爱必信(上海)生物科技有限公司
地址:上海市浦东新区新浩路58号申江科创园18栋
邮箱:lanwu@univ-bio.com
传真:
关注我们
欢迎您关注我们的微信公众号了解更多信息:
欢迎您关注我们的微信公众号
了解更多信息